Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 16/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 12/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.37 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | PGK2 | P07205 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7230645 | 0.95 | ADORA2A (0.45) | ADORA2AADORA3ADORA2BADORA1PGK1 | |
| SCHEMBL7230061 | 0.93 | ADORA2A (0.46) | ADORA2AADORA3ADORA2BADORA1 | |
| Formic Acid SCHEMBL7230638 | 0.91 | ADORA2A (0.47) | ADORA2AADORA3ADORA2BADORA1PGK1 | |
| SCHEMBL7222870 | 0.91 | ADORA2A (0.48) | ADORA2AADORA3ADORA2BADORA1PGK1 | |
| SCHEMBL7452023 | 0.90 | ADORA3 (0.48) | ADORA2AADORA3ADORA2BADORA1PGK1 | |
| SCHEMBL7230202 | 0.89 | PGK1 (0.50) | ADORA2AADORA3ADORA2BADORA1PGK1 | |
| SCHEMBL7224024 | 0.89 | ADORA2A (0.41) | ADORA2AADORA3ADORA2BADORA1PGK1 | |
| SCHEMBL7230742 | 0.88 | ADORA2A (0.55) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL7230064 | 0.88 | ADORA2A (0.46) | ADORA2AADORA3ADORA2BADORA1PGK1 | |
| SCHEMBL7224964 | 0.88 | PGK1 (0.45) | ADORA2AADORA3ADORA2BADORA1PGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6528494-B2 | Antiinflammatory agents | COX BRIAN (GB) | 2003-03-04 | — | — | US | disclosed |
| EP-0948509-B1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LTD (GB) | 2002-10-16 | — | — | EP | disclosed |
| US-6426337-B1 | ANTIINFLAMMATORY AGENTS | SMITHKLINE BEECHAM CORPORATION | 2002-07-30 | — | — | US | disclosed |
| US-20020086850-A1 | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives | COX BRIAN (GB) | 2002-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086850-A1 | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives | PURB, P2RX3, P2RY2 | ADORA2A 202/4885ADORA3 182/4885ADORA2B 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.